RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
 Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Sep 15, 2017 - 4:49:58 AM
Research Article
Latest Research Channel

subscribe to Latest Research newsletter
Latest Research

   EMAIL   |   PRINT
Tuberculosis international conference: April 13-14 at Emory University

Mar 22, 2012 - 4:00:00 AM

Our Atlanta conference is very timely in light of rapid growth in interest, facilities, and systems for specific studies of human immune responses to TB, says Rengarajan. By bringing together investigators with experience in developing and applying novel approaches to studying human immune responses and investigators from regions of high TB incidence, we will promote interactions and enable future collaborations that should have a significant impact on this important field.


 
[RxPG] Leading international experts in tuberculosis and related diseases from at least 10 countries will gather at a Human Immunity to Tuberculosis conference April 13-14 in Atlanta. The meeting will take place at the Emory Conference Center, 1615 Clifton Rd., Atlanta, GA 30329.

This first international conference devoted to human immunity to tuberculosis will advance the study of human immunity to Mycobacterium tuberculosis and determine critical areas of focus in TB research. Participants will identify important knowledge gaps and roadblocks to understanding the mechanisms of human immunity to TB and their limitations.

Organizers include Drs. Jyothi Rengarajan (Emory Vaccine Center), Joel Ernst (NYU School of Medicine), Willem Hanekom (South African TB Vaccine Initiative and University of Cape Town), Tom Hawn (University of Washington), and Beate Kampmann (Imperial College and Medical Research Council Laboratories, the Gambia).

Tuberculosis is a serious global health problem that causes about two million deaths each year, says Rengarajan. TB is particularly deadly in combination with HIV and is the leading cause of death in people infected with HIV. Developing an effective vaccine to prevent TB is clearly an important goal but in order to do that we need to better understand the protective and pathological immune responses against the causative agent in humans, Mycobacterium tuberculosis.

One-third of the world's population is infected with TB, according to the Centers for Disease Control and Prevention, and each year nine million people become sick with the disease, resulting in nearly two million related deaths. In 2010 more than 11,000 cases of TB were reported in the United States.

Tuberculosis is an important area of research at the Emory Vaccine Center, where Rengarajan and her group work to understand how M. tuberculosis causes disease as well as how the immune system responds to infection. In collaboration with Susan Ray, MD, associate professor of medicine in Emory University School of Medicine and an infectious disease clinician at Grady Memorial Hospital and the Fulton County Health Departments, they are studying how the immune response is regulated in patients with TB disease and in healthy individuals with latent TB infection.

Many people are surprised to learn that Atlanta has approximately new 150 TB cases per year and that the TB rates in Georgia are among the highest in the country, notes Rengarajan. Emory Vaccine Center scientists also will be increasing their research focus on human immunity to TB through international collaborations in South Africa and India.

Our Atlanta conference is very timely in light of rapid growth in interest, facilities, and systems for specific studies of human immune responses to TB, says Rengarajan. By bringing together investigators with experience in developing and applying novel approaches to studying human immune responses and investigators from regions of high TB incidence, we will promote interactions and enable future collaborations that should have a significant impact on this important field.

Conference sponsors include Emory University, the Bill and Melinda Gates Foundation, BD Biosciences, GlaxoSmithKline Biologicals, The Potts Memorial Foundation, Cellestis, the Tuberculosis Vaccine Initiative, Biologend, Oxford Immunotec and the European Respiratory Society.



Related Latest Research News


Subscribe to Latest Research Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

Online ACLS Certification

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)